Amplia Therapeutics Presents Mature Data from ACCENT Trial at AACR Annual Meeting
Amplia Therapeutics presented mature data from its ACCENT trial on narmafotinib in combination with chemotherapy for pancreatic cancer at the AACR annual meeting. The data showed a 36% response rate and 70% disease control rate, with improved survival compared to chemotherapy alone. The trial highlights the potential of narmafotinib as a FAK inhibitor in oncology.
Topics: AACR Conference Clinical Trials Pancreatic Cancer Pharmaceuticals